NCT01001767

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

Prospective Randomized Placebo Controlled Trial of Omega-3 Fatty Acids in HIV Infected Subjects to Modulate Cardiovascular Risk

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Several studies have shown that there is an increased risk of heart disease in people with HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid) on improving endothelial function and decreasing inflammation which may contribute to this increased risk. The investigators will also be doing studies to analyze coagulation and inflammation markers.

Conditions

• HIV Infections
• Heart Disease

Interventions

Type	Name	Description
DRUG	Lovaza	Lovaza one gram twice a day for 24 weeks
DRUG	Placebo	Placebo

Timeline

• Start date: 2009-04-01
• Primary completion: 2010-03-01
• Completion: 2010-06-01
• First posted: 2009-10-27
• Last updated: 2015-01-07
• Results posted: 2012-04-09

Locations

1 site across 1 country: United States